Literature DB >> 16353330

[The significance of sickle cell anemia within the context of the Brazilian government's 'racial policies' (1995-2004)].

Peter H Fry1.   

Abstract

This essay reflects on the social significance of growing interest in sickle cell anemia and other illnesses associated with the black body in Brazil. I explore the discursive network that has taken shape around the disease within the social context of its production. I first summarize anthropologist Melbourne Tapper's analysis of the United States program to fight sickle cell anemia in the 1970s, shortly after blacks attained victories in the civil rights movement. Tapper (1999) argues that one of the consequences of this policy was the creation of a responsible black citizenry. In the late 1990s, the Brazilian government developed a program (Programa de Anemia Falciforme) that counted on the heavy participation of black activists and that also contributed to the formation of a "responsible black community". My argument is that sickle cell anemia becomes much more than an illness to be eradicated. The discourse surrounding it is a powerful element in the process of naturalization of the "black race" (and, by logical and political complement, the "white race") in a country that until recently imagined itself a biologically and culturally hybrid nation.

Entities:  

Mesh:

Year:  2005        PMID: 16353330     DOI: 10.1590/s0104-59702005000200007

Source DB:  PubMed          Journal:  Hist Cienc Saude Manguinhos        ISSN: 0104-5970


  3 in total

1.  Claude Lévi-Strauss on Race, History, and Genetics.

Authors:  Staffan Müller-Wille
Journal:  Biosocieties       Date:  2010-09-01

2.  Genetics against race: Science, politics and affirmative action in Brazil.

Authors:  Michael Kent; Peter Wade
Journal:  Soc Stud Sci       Date:  2015-12       Impact factor: 3.885

3.  Normalcy, Race, and Biomedical Technology in Brazil: The Case of Low White Blood Cell Count.

Authors:  Elena Calvo-González
Journal:  Front Sociol       Date:  2019-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.